Physician profile
Ananth Sastry
NPI 1740693936
$43,614.26
in general payments reported to CMS, 2019-2025
15 companies · $17K in 2025
The $17K reported for 2025 was more than what 93% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $118 · 2022: $16K · 2023: $1,858 · 2024: $7,387 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,200 · Travel and Lodging: $3,448 · Food and Beverage: $2,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,682.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,200.00 |
| Travel and Lodging | $3,448.01 |
| Food and Beverage | $2,525.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $8,573.04 | 2025 | Cirrus 6000 With Angioplex, Clarus, Quatera 700 |
| Genentech USA, INC. | $7,337.66 | 2019-2022 | |
| Abbvie INC. | $7,026.63 | 2022-2024 | |
| Apellis Pharmaceuticals, INC. | $6,682.02 | 2022-2024 | Syfovre |
| Carl Zeiss Meditec, INC. | $4,940.92 | 2025 | Cirrus Hd-Oct, Quatera 700, Cirrus 6000 With Angioplex |
| Harrow Eye, LLC | $2,800.00 | 2025 | Triesence |
| Bausch & Lomb Americas INC. | $2,511.79 | 2023-2025 | Stellaris Elite, Miebo, Xiidra |
| Dutch Ophthalmic, USA | $1,272.20 | 2023-2025 | Eva, Combined Machine, Tissueblue |
| Regeneron Pharmaceuticals, INC. | $1,258.86 | 2019-2023 | Eylea |
| Alimera Sciences, INC. | $464.23 | 2023-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $341.41 | 2019-2025 | Constellation, Rocklatan, Centurion |
| Regeneron Healthcare Solutions, INC. | $192.82 | 2023 | Eylea Hd |
| Ocular Therapeutix, INC. | $96.38 | 2020-2023 | Dextenza |
| Genentech, INC. | $91.02 | 2020 | |
| Ani Pharmaceuticals, INC. | $25.28 | 2025 | Yutiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ananth Sastry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.